What is a KRAS mutation in non-small cell lung cancer (NSCLC)?

Unlocking Cancer Treatment Gene Mutation InsightsПодробнее

Phase III trial of divarasib versus adagrasib or sotorasib in KRAS G12C-m NSCLCПодробнее

Phase I trial of ASP3082 in KRAS G12D-positive solid tumorsПодробнее

CRSF 7th Masterclass | 1st Line Therapy Selection for KRAS in Lung Cancer by Dr. Akhil KapoorПодробнее

An Overview of KRAS+ NSCLC and Diagnostic Testing - LCVL 2024Подробнее

Any role of Chemotherapy in high PDL1 metastatic non-small cell lung cancer in 1L?Подробнее

Discover Sotorasib Tablet: Uses, Dosage, Mechanism, Side Effects & Vital Tips | MediInsightsПодробнее

The role of checkpoint inhibitors in KRAS-mutated NSCLCПодробнее

Unlocking KRAS Mutations in CancerПодробнее

CRSF 7th Masterclass | Interpreting KRAS Mutation in Lung Cancer by Dr. Rushabh Kothari | Day 3Подробнее

What's on the Horizon for KRAS-Mutated NSCLC?Подробнее

Terri - How has your KRAS mutation affected the treatment options available to you?Подробнее

Exploring estrogen receptor roles and targeted therapy in NSCLCПодробнее

What is a MET mutation in non-small cell lung cancer (NSCLC)?Подробнее

How to Treat Metastatic Non-Small Cell Lung Cancer w/o Targeted Mut in Front-line - Dr. PreeshagulПодробнее

How do doctors treat lung cancer with KRAS mutations?Подробнее

Understanding NSCLC Treatment When You Have a KRAS MutationПодробнее

Personalized cancer treatment with ER inhibition strategies for NSCLCПодробнее

Understanding NSCLC Treatments for Less Common Mutations: ALK, BRAF, ROS1, HER2, METПодробнее

Terri - How did you find out you had KRAS-positive lung cancer?Подробнее